Today Adma Biologics (Nasdaq: ADMA) sold off ~10% closing at $3.50. Most of us already in Adma were not phased. Personally, I saw this as a healthy pullback. Since February 1st ADMA has gained 25% … [Read more...] about ADMA Presents Potential Entry For Investors On The Sideline
Today ADMA Biologics (Nasdaq: ADMA) announced that they entered into a senior secured loan term facility with Perceptive Advisors for up to $72.5 million under 2 funding tranches. Let's get clarify … [Read more...] about ADMA Enters Into $72.5 Million Loan Facility With Perceptive Advisors
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Preface WOW. We are absolutely elated with the performance of our last swing move on SCYX. In case you missed it on … [Read more...] about MS Identified Its Next Swing
Introduction Adma Biologics (Nasdaq: ADMA $2.23) is a commercial bio-pharmaceutical company vertically integrated to develop, market, manufacture, and sell specialty plasma-derived products called … [Read more...] about ADMA Tanks After Receiving A CRL For BIVIGAM’s PAS Submission -Should You Buy?
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath